Minority patients with aggressive B-cell lymphoma experienced equitable outcomes through more accessible care and the use of the nurse navigators.
Low-dose rotational total skin electron beam therapy helped to improve skin-related quality of life and yielded promising responses among patients with mycosis fungoides.
Pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin appears to be a successful bridging regimen for patients with relapsed/refractory classical Hodgkin lymphoma.
Patients with relapsed/refractory Waldenströms macroglobulinemia benefited from treatment with ixazomib, rituximab, and dexamethasone and maintained a tolerable safety profile.
FT596 and FT516 natural killer cell products elicited promising responses in a population of patients with B-cell lymphoma.
The accelerated approval status for romidepsin for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma has been withdrawn following the results of the confirmatory phase 3 Ro-CHOP trial.
Zanubrutinib yielded a high response rate and extended progression-free survival in patients with relapsed/refractory mantle cell lymphoma.
Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.
For patients with large B-cell lymphoma who have undergone treatment with axicabtagene ciloleucel, ctDNA monitoring may help to improve early detection of recurrent disease.
Patients in the ZUMA-7 trial who were assigned Yescarta (axicabtagene ciloleucel) saw event-free survival by 60% compared to patients who were on a chemotherapy plus stem cell regimen.